BATF3 and psoriasis: This was true for all markers investigated: RHCG (91 versus 9-fold up-regulation), TCN1 (285 versus 8-fold up-regulation), KLK6 50 versus 5-fold up-regulation), and LCN2 (18 versus 3-fold up-regulation) in psoriasis and CCL17 (1-fold versus 10-fold up-regulation), NCF4 (1.4-fold versus 3-fold up-regulation), BATF3 (3-fold versus 14-fold up-regulation), and CLEC4G (3-fold versus 6-fold up-regulation) in ACD.